LIVEKIDNEY.BIO

Company Overview

Snapshot

Founded in November 2009, LIVEKIDNEY.BIO operates with 1–10 employees and has raised $4 million across one funding round from 2 investors. The company focuses on developing regenerative medicine therapies for kidney disease.

Business overview

LIVEKIDNEY.BIO is a biotechnology company dedicated to developing proprietary cell-derived delivery platforms to improve the health and life of patients with kidney disease. Its core technology integrates sustained-release hydrogel formulations with AI-enabled data analytics. The company's novel AI-based cell-derived therapy aims to ameliorate kidney function in patients with chronic kidney disease and improve the general medical condition of patients with Lupus. LIVEKIDNEY.BIO operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development markets.

Strategic signal

In February 2019, LIVEKIDNEY.BIO was highlighted for its efforts in delaying dialysis for patients with chronic kidney disease. This signals the company's potential to offer a significant medical advancement in nephrology, addressing a critical need in patient care and potentially reducing the economic burden of kidney disease.

Company Intelligence Q&A

What is LIVEKIDNEY.BIO's primary focus?

LIVEKIDNEY.BIO is focused on developing regenerative medicine therapies for kidney disease, utilizing a proprietary cell-derived delivery platform.

When was LIVEKIDNEY.BIO founded?

LIVEKIDNEY.BIO was founded in November 2009.

How much capital has LIVEKIDNEY.BIO raised?

LIVEKIDNEY.BIO has raised a total of $4 million across one funding round.

What is the core technology behind LIVEKIDNEY.BIO's therapies?

The company's technology is based on sustained-release hydrogel formulations combined with AI-enabled data analytics, designed to ameliorate kidney function.

What was a notable news highlight for LIVEKIDNEY.BIO?

In February 2019, LIVEKIDNEY.BIO was featured for its work in delaying dialysis for patients with chronic kidney disease, showcasing the potential impact of its therapies.